ArticleCurrent medicinal chemistry2026
VAPB Promotes Osteogenic Differentiation in Aortic Valve Interstitial Cells via Activation of the SMAD Signaling Pathway.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrior studies have associated vesicle-associated membrane protein- associated protein B (VAPB) with various cardiovascular diseases, yet its role in calcific Aortic Valve Disease (CAVD) is not fully understood. This study aims to elucidate the relationship between VAPB and aortic valve calcification at both tissue and cellular molecular levels, exploring potential regulatory mechanisms.
methodsThe expression levels of VAPB in calcified valve tissues were assessed using immunohistochemical analysis. Osteogenic differentiation and calcification levels of valve interstitial cells (VICs) were evaluated by alizarin red staining, calcium content quantification, and the detection of the osteogenic markers. Gene set enrichment analysis (GSEA) was used to identify downstream pathways regulated by VAPB, immunoblotting was used to detect the expression of key molecules of SMAD signaling, and immunoprecipitation was performed to detect interactions between VAPB and SMAD1/5/9.
resultsVAPB expression was significantly upregulated in the aortic valve leaflets of patients with CAVD. VICs with VAPB overexpression exhibited a significant increase in calcium content (p < 0.001) and upregulation of osteogenic markers RUNX2, osteocalcin, and osteopontin (p <0. 01). Conversely, VAPB knockdown reduced osteogenic differentiation in VICs. Furthermore, VAPB overexpression led to the enhanced expression of p-SMAD1/5/9 through activation of the SMAD signaling pathway (p < 0.05), while inhibition of the SMAD pathway abrogated the pro-calcification effects of VAPB. Dual immunofluorescence staining demonstrated colocalization of VAPB with SMAD1/5/9, and immunoprecipitation confirmed an interaction between VAPB and SMAD1/5/9.
conclusionThe findings indicate that VAPB promotes osteogenic differentiation in aortic valve interstitial cells by activating the SMAD signaling pathway.
Indexed as
Identifiers
41384334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.